70 results on '"carla minoia"'
Search Results
2. Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi
- Author
-
Stefano Luminari, Luca Guerra, Carla Minoia, Stephane Chauvie, Antonella Anastasia, Federica Cavallo, Paolo Corradini, Sara Rattotti, Rexhep Durmo, Chiara Ghiggi, Jacopo Olivieri, Simone Ferrero, Gloria Margiotta Casaluci, Luca Nassi, Caterina Stelitano, Francesca Ricci, Vittorio Ruggero Zilioli, Antonio Pinto, Manuela Zanni, Bolis Silvia, Caterina Patti, Michele Merli, Annalisa Chiarenza, Gerardo Musuraca, Patrizia Tosi, Massimo Federico, and Annibale Versari
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
3. Supplementary Table 2 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 23K, Proteins identified in MMECs upon HIF-1�siRNA and panobinostat treatment (MALDITOFF mass spectrometry).
- Published
- 2023
4. Supplementary Figure 1 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 114K, Lack of HIF-1alpha expression by BM macrophages in normoxia condition.
- Published
- 2023
5. Supplementary Figure 4 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 2376K, Panobinostat effect on MMECs in the presence of BM cells and proteomic analysis of MMECs upon treatment with HIF-1α·siRNA or panobinostat.
- Published
- 2023
6. Supplementary Figure 2 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 133K, HIF-1alpha protein correlates with VEGFR-2, FGFR-2 and HGF.
- Published
- 2023
7. Supplementary Table 1 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 17K, Real Time RT-PCR Primers.
- Published
- 2023
8. Supplementary Figure 5 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 166K, HIF-1alpha protein does not correlate with AKT, and VHL.
- Published
- 2023
9. Data from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
Purpose: To investigate the role of hypoxia-inducible factor-1α (HIF-1α) in angiogenesis and drug resistance of bone marrow endothelial cells of patients with multiple myeloma.Experimental Design: HIF-1α mRNA and protein were evaluated in patients with multiple myeloma endothelial cells (MMEC) at diagnosis, at relapse after bortezomib- or lenalidomide-based therapies or on refractory phase to these drugs, at remission; in endothelial cells of patients with monoclonal gammapathies of undetermined significance (MGUS; MGECs), and of those with benign anemia (controls). The effects of HIF-1α inhibition by siRNA or panobinostat (an indirect HIF-1α inhibitor) on the expression of HIF-1α proangiogenic targets, on MMEC angiogenic activities in vitro and in vivo, and on overcoming MMEC resistance to bortezomib and lenalidomide were studied. The overall survival of the patients was also observed.Results: Compared with the other endothelial cell types, only MMECs from 45% of relapsed/refractory patients showed a normoxic HIF-1α protein stabilization and activation that were induced by reactive oxygen species (ROS). The HIF-1α protein correlated with the expression of its proangiogenic targets. The HIF-1α inhibition by either siRNA or panobinostat impaired the MMECs angiogenesis–related functions both in vitro and in vivo and restored MMEC sensitivity to bortezomib and lenalidomide. Patients with MMECs expressing the HIF-1α protein had shorter overall survival.Conclusions: The HIF-1α protein in MMECs may induce angiogenesis and resistance to bortezomib and lenalidomide and may be a plausible target for the antiangiogenic management of patients with well-defined relapsed/refractory multiple myeloma. It may also have prognostic significance. Clin Cancer Res; 20(4); 847–58. ©2013 AACR.
- Published
- 2023
10. Supplementary Figure 3 from HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- Author
-
Angelo Vacca, Franco Dammacco, Michele Moschetta, Daniele Derudas, Emanuele Angelucci, Paolo Ditonno, Carla Minoia, Attilio Guarini, Simona Ruggieri, Tiziana Annese, Beatrice Nico, Domenico Ribatti, Maria Antonia Frassanito, Vitalba Ruggieri, Claudia Piccoli, Antonella Caivano, Annunziata De Luisi, Simona Berardi, Ivana Catacchio, and Roberto Ria
- Abstract
PDF file - 403K, HIF-1alpha protein negative MMECs are sensitive to the antiangiogenic effect of bortezomib and lenalidomide.
- Published
- 2023
11. 2022-RA-595-ESGO Ovarian stem cells from cryopreserved ovarian cortex: a potential for neo-oogenesis in women with cancer-treatment related infertility
- Author
-
Erica Silvestris, Carla Minoia, Ambrogio Cazzolla, Anila Kardhashi, Giuseppe de Palma, Francesca Arezzo, Vera Loizzi, Raffaella de Palo, Miriam Dellino, and Gennaro Cormio
- Published
- 2022
12. 2022-RA-1040-ESGO Nutritional supplementation with myo-inositol-D-chiro-inositol: effect on reproductive system functionality in long-term survivors of lymphoma
- Author
-
Miriam Dellino, Gennaro Cormio, Carla Minoia, Attilio Guarini, Erica Silvestris, Raffaella Depalo, Antonio Malvasi, Giovanni Di Vagno, Vera Loizzi, Gerardo Cazzato, Eliano Cascardi, Vito Chiantera, and Antonio Simone Laganà
- Published
- 2022
13. Risk of Unemployment Among Chronic Myeloproliferative Disorders Patients
- Author
-
Paolo Ditonno, Luigi DI Lorenzo, Antonella Pipoli, Carla Minoia, Ilaria Maria DI Somma, Fulvia Lagattolla, Francesca Romito, Maria Giorgia D'alonzo, Emanuela Filomena Laddaga, Vincenza De Fazio, and Attilio Guarini
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
14. Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure
- Author
-
Carla Minoia, Davide Bavaro, Giacomo Loseto, Crescenza Pasciolla, Lucia Diella, Carmen Pelligrino, Valentina Totaro, Vito Spada, Michele Camporeale, Immacolata Attolico, Tommasina Perrone, Felice Clemente, Francesco di Gennaro, Pellegrino Musto, Attilio Guarini, and Annalisa Saracino
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
15. Ovarian Stem Cells (OSCs) from the Cryopreserved Ovarian Cortex: A Potential for Neo-Oogenesis in Women with Cancer-Treatment Related Infertility: A Case Report and a Review of Literature
- Author
-
Erica Silvestris, Carla Minoia, Attilio Guarini, Giuseppina Opinto, Antonio Negri, Miriam Dellino, Raffaele Tinelli, Gennaro Cormio, Angelo Virgilio Paradiso, and Giuseppe De Palma
- Subjects
Microbiology (medical) ,General Medicine ,Molecular Biology ,Microbiology - Abstract
Cancer treatment related infertility (CTRI) affects more than one third of young women undergoing anti-cancer protocols, inducing a premature exhaustion of the ovarian reserve. In addition to ovarian suppression by GnRHa, oocyte and cortex cryopreservation has gained interest in patients with estrogen-sensitive tumors for whom the hormonal burst to prompt the multiple follicular growth could provide a further pro-life tumor pulsing. On the other hand, cortex reimplantation implies a few drawbacks due to the unknown consistency of the follicles to be reimplanted or the risk of reintroducing malignant cells. The capability of ovarian stem cells (OCSs) from fresh ovarian cortex fragments to differentiate in vitro to mature oocytes provides a tool to overcome these drawbacks. In fact, since ovarian cortex sampling and cryopreservation is practicable before gonadotoxic treatments, the recruitment of OSCs from defrosted fragments could provide a novel opportunity to verify their suitability to be expanded in vitro as oocyte like cells (OLCs). Here, we describe in very preliminary experiments the consistency of an OSC population from a single cryopreserved ovarian cortex after thawing as well as both their viability and their suitability to be further explored in their property to differentiate in OLCs, thus reinforcing interest in stemness studies in the treatment of female CTRI.
- Published
- 2022
16. The Role of Circulating Adiponectin and SNP276G>T at ADIPOQ Gene in BRCA-mutant Women
- Author
-
Porzia Casamassima, Brunella Pilato, Maria Digennaro, Antonella Daniele, Rosa Divella, Eufemia Savino, Eleonora Bruno, Margherita Patruno, Carla Minoia, Patrizia Pasanisi, Stefania Tommasi, Michele Barone, Antonio Tufaro, Andreina Oliverio, Donatella Colangelo, and Angelo Paradiso
- Subjects
Cancer Research ,medicine.medical_specialty ,Adiponectin ,business.industry ,Leptin ,BRCA mutation ,Case-control study ,Adipokine ,Odds ratio ,Biochemistry ,Penetrance ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,030220 oncology & carcinogenesis ,Internal medicine ,Genotype ,Genetics ,Medicine ,business ,Molecular Biology - Abstract
Background Environmental factors may influence the lifetime risk of cancer (penetrance) in women with a BRCA mutation. Materials and methods In 89 BRCA-mutant women, affected or unaffected by breast/ovarian cancer, we explored serum levels of adipokines and their relation with the polymorphism SNP276G>T as modulators of BRCA penetrance. Results Affected women had significantly lower adiponectin than healthy women. Affected women with rs1501299 TT had significantly lower adiponectin and higher leptin than GT and GG genotypes. GT genotype was significantly associated with the disease status [odds ratio (OR)=3.24, 95% confidence interval (95% CI)=1.03-10.17]. Women in the lower tertile of serum adiponectin had a RR of BRCA-associated cancer of 2.80, 95% CI=1.1-7.1 (p for trend=0.03) compared with women in the higher tertile. Conclusion In the SNP rs1501299 the T allele was significantly associated with lower serum levels of adiponectin in affected women, suggesting that the T allele might be related to cancer.
- Published
- 2020
17. Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkin's Lymphoma: The Tei Index Evaluation
- Author
-
Agata Puzzovivo, Agnese Maria Fioretti, Carla Minoia, Roberta Villoni, Santa Carbonara, Giusi Graziano, Fabio Pavone, Attilio Guarini, and Stefano Oliva
- Subjects
Medicine (miscellaneous) - Abstract
Anthracyclines are widely employed in lymphoma’s chemotherapy and has been shown to induce heart failure. Echocardiographic parameters of left ventricular (LV) systolic function are usually used to monitor the cardiac side effects during and after anthracyclines treatment. The measurement of theTei index could anticipate the onset of LV dysfunction. The aim of this study was to evaluate the performance of the delta Tei index for the early detection of cardiac toxicity in a prospective population of anthracycline-treated lymphoma patients. Our preliminary data suggest that the Tei index may predict the risk for cardiotoxicity in this subset of patients earlier than LV ejection fraction alteration.
- Published
- 2021
18. Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology
- Author
-
Gian Maria Zaccaria, Vito Colella, Simona Colucci, Felice Clemente, Fabio Pavone, Maria Carmela Vegliante, Flavia Esposito, Giuseppina Opinto, Anna Scattone, Giacomo Loseto, Carla Minoia, Bernardo Rossini, Angela Maria Quinto, Vito Angiulli, Luigi Alfredo Grieco, Angelo Fama, Simone Ferrero, Riccardo Moia, Alice Di Rocco, Francesca Maria Quaglia, Valentina Tabanelli, Attilio Guarini, and Sabino Ciavarella
- Subjects
Research Report ,Multidisciplinary ,B-cell lymphoma ,Science ,Data acquisition ,Disease Management ,Diagnostic markers ,Hematology ,Translational research ,Medical Oncology ,Article ,Workflow ,Pathology ,Humans ,Electronic Health Records ,Medicine ,Data integration ,Natural Language Processing - Abstract
The unstructured nature of Real-World (RW) data from onco-hematological patients and the scarce accessibility to integrated systems restrain the use of RW information for research purposes. Natural Language Processing (NLP) might help in transposing unstructured reports into standardized electronic health records. We exploited NLP to develop an automated tool, named ARGO (Automatic Record Generator for Onco-hematology) to recognize information from pathology reports and populate electronic case report forms (eCRFs) pre-implemented by REDCap. ARGO was applied to hemo-lymphopathology reports of diffuse large B-cell, follicular, and mantle cell lymphomas, and assessed for accuracy (A), precision (P), recall (R) and F1-score (F) on internal (n = 239) and external (n = 93) report series. 326 (98.2%) reports were converted into corresponding eCRFs. Overall, ARGO showed high performance in capturing (1) identification report number (all metrics > 90%), (2) biopsy date (all metrics > 90% in both series), (3) specimen type (86.6% and 91.4% of A, 98.5% and 100.0% of P, 92.5% and 95.5% of F, and 87.2% and 91.4% of R for internal and external series, respectively), (4) diagnosis (100% of P with A, R and F of 90% in both series). We developed and validated a generalizable tool that generates structured eCRFs from real-life pathology reports.
- Published
- 2021
19. Fertility preservation techniques in cervical carcinoma
- Author
-
Erica Silvestris, Angelo Virgilio Paradiso, Carla Minoia, Antonella Daniele, Gennaro Cormio, Raffaele Tinelli, Stella D’Oronzo, Paola Cafforio, Vera Loizzi, and Miriam Dellino
- Subjects
Cryopreservation ,Carcinoma ,Oocytes ,Fertility Preservation ,Humans ,Oocyte Retrieval ,Uterine Cervical Neoplasms ,Female ,General Medicine - Abstract
The usefulness of this review is to highlight how a fertility preservation (FP) approach is currently feasible for patients diagnosed with uterine cervical cancer. To this regard, a fertility sparing surgery has just overcome its traditional limits, gained acceptance within the major gynecologic oncology societies thanks to the ability to identify the "ideal" candidates to this conservative treatment. On the other hand, the use of other FPs for oocyte and ovarian cortex cryopreservation is still extremely debated. In fact, the existing risk of tumor spreading during oocyte retrieval necessary for oocyte cryostorage for patients' candidates for neo-adjuvant therapy, as well as the potential hazard of cancer cell dissemination after ovarian tissue replacement in cases of non-squamous type cervical carcinomas should not be underestimated. Therefore, in consideration of the encountered limitations and the need to ensure adequate reproductive health for young uterine cervical cancer survivors, translational research regarding the FP has progressively collected innovative insights into the employment of stemness technology. In this context, the property of ovarian stem cells obtained from the ovarian cortex to generate functional oocytes in women could represent a promising therapeutic alternative to the current procedures for a novel and safer FP approach in cancer survivors.
- Published
- 2021
20. Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
- Author
-
Sergio Di Molfetta, Antonella Daniele, Chiara Gerardi, Eleonora Allocati, Carla Minoia, Giacomo Loseto, Francesco Giorgino, Attilio Guarini, and Vitaliana De Sanctis
- Subjects
sarcopenia ,Cancer Research ,Oncology ,lymphoma survivors ,gonadal dysfunction ,diffuse large B‐cell lymphoma ,Classical Hodgkin lymphoma ,metabolic syndrome ,osteoporosis ,thyroid disease - Abstract
Background: Overall survival after lymphoma has improved in recent years, but the high prevalence of late treatment-related sequelae has been observed as a counterpart. Method: In this systematic review, FIL researchers aimed to: (i) estimate the incidence or prevalence of late endocrine-metabolic sequelae, (ii) evaluate the effects of modern therapeutic approaches on incidence or prevalence of late endocrine-metabolic sequelae, and (iii) determine whether there is evidence of follow-up schemes for their screening/early diagnosis in the subset of long-term classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) survivors treated at adult age. The MEDLINE, Embase and the Cochrane Library databases were searched for relevant articles published up to October, 2020. The study selection process was conducted by three independent reviewers and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A risk of bias assessment was performed using the Cochrane tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. Results: In the final analysis, eight studies were included, four of which focused on thyroid disease, two on gonadal dysfunction, one on bone disease and one on metabolic syndrome. Hypothyroidism was reported in up to 60% of adult cHL survivors and was frequently recorded even with modern radiotherapy approaches. Menopause occurred in 52–72% of women after chemotherapy. An 86% reduction in vertebral density was reported following R-CHOP-like chemotherapy. Sarcopenia and metabolic syndrome were reported in 37.9% and 60% of patients, respectively. No validated screening protocols were found for the early diagnosis of long-term treatment-related endocrine and metabolic sequelae, thus the authors finally suggest the execution of screening exams according to the risk category which were identified in the epidemiologic studies.
- Published
- 2021
21. Psychological well-being in cancer outpatients during COVID-19
- Author
-
Daniela, Bafunno, Francesca, Romito, Fulvia, Lagattolla, Vito Antonio, Delvino, Carla, Minoia, Giacomo, Loseto, Miriam, Dellino, Attilio, Guarini, Annamaria, Catino, Michele, Montrone, Vito, Longo, Pamela, Pizzutilo, Domenico, Galetta, Francesco, Giotta, Agnese Carmela, Latorre, Anna, Russo, Vito, Lorusso, and Claudia, Cormio
- Subjects
Adult ,Aged, 80 and over ,Male ,Depression ,SARS-CoV-2 ,COVID-19 ,Anxiety ,Middle Aged ,Young Adult ,Cross-Sectional Studies ,Neoplasms ,Surveys and Questionnaires ,Outpatients ,Humans ,Female ,Stress, Psychological ,Aged - Abstract
The psychological status of cancer outpatients receiving anti-neoplastic treatment during the lockdown in a Italian non-COVID Cancer Center, was been investigated with the following aims: to measure the levels of post-traumatic stress symptoms, depression and anxiety; to compare patients with different cancer sites; to compare the anxiety and depression levels measured in this emergency period between cancer and non-cancer patients and between cancer patients before and after the emergency.The following questionnaires were used: The Hospital Anxiety and Depression Scale (HADs) and the Impact of Event Scale-Revised (IES-R).Worries regarding the COVID-19 on patients' lives, socio-demographic and clinical details were collected using a brief structured questionnaire.One-hundred seventy-eight outpatients were enrolled. We found that 55% of patients were above the cut-off for HADS general scale and 23.7% had severe level of PTSD. The 68% of patients declared that their worries have increased during the pandemic especially for women. Patients with lung cancer have higher general distress compared with patients with breast cancer and lymphoma. The non cancer sample had values significantly higher both for the IES-R scales and for HADS Depression subscale. Finally, cancer patients who experienced the health emergency showed higher levels of anxiety than those measured 2 years ago.Cancer out-patients of the present sample have severe post-traumatic stress symptoms and psychological distress, those with lung cancer are at higher risk and may need special attention. Non-oncological subjects have higher depression levels than cancer patients.
- Published
- 2021
22. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
- Author
-
Juliana Pereira, Astrid Pavlovsky, Eliza A Hawkes, A. Lymboussakis, I. Kryachok, Lorena Fiad, R. Nair, Carla Minoia, C.A. De Souza, C.S. Chiattone, R. Advani, Stefano Luminari, H. M. Prince, Massimo Federico, Martina Manni, Tetiana Skrypets, C. Tomuleasa, N. S. De Castro, P. Pereyra, and Monica Civallero
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,T cell ,Hematology ,General Medicine ,medicine.disease ,Lymphoma ,Leukemia ,medicine.anatomical_structure ,Preliminary report ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Who classification ,Prospective cohort study ,business ,Anaplastic large-cell lymphoma - Abstract
Introduction: Mature T and NK-cell lymphomas represent a heterogeneous group of lymphoid disorders (29 subtypes according to the 2016 WHO classification) arising from mature T cells of post-thymic origin with different morphological characteristics, phenotypes, and clinical presentation. Following the success of the T Cell Project (TCP), which allowed the analysis of more than 1,500 cases of peripheral T-Cell lymphomas (PTCLs) collected prospectively in 18 Countries, in 2018 the TCP 2.0 was launched. Here we report the global distribution of PTCLs, from the cases registered so far based on the locally established histological diagnosis. Methods: The TCP2.0 (ClinicalTrials.gov Identifier: NCT03964480) is a prospective, international, observational study which adapts to changes made in the new WHO classification. Results: Since the beginning of the study (October 2018), 648 patients with newly diagnosed PTCL were registered by 75 active centers across 14 countries. Of these data, 594 patients have been validated by the centralized trial office. Overall, PTCL-NOS, Anaplastic large cell lymphoma (ALCL) ALK-negative, and Angioimmunoblastic T-cell lymphoma (AITL), represent the most frequent subtypes, representing 31.3%, 18,9% and 13,5% of cases, respectively. As reported in Table 1, PTCL-NOS represents the most frequent subtype worldwide, whereas Adult T-cell leukemia/lymphoma was more frequent in Brazil, AITL and ALCL ALK-negative in Australia/ India, and ALCL ALK-positive in North America and Europe. Extranodal NK/T-cell lymphoma, nasal type was relatively frequent in Brazil and quite rare in the other Latin America Countries. Finally, many sub-types represent less than 5% of cases in all geographic areas. Conclusions: The TCP2.0 continues to recruit very well, despite the difficulties linked to the COVID-19 pandemic, and may represent a useful resource for the prospective study of this group of rare lymphomas.
- Published
- 2021
23. Association between Cervical Microbiota and HPV: Could This Be the Key to Complete Cervical Cancer Eradication?
- Author
-
Eliano Cascardi, Gerardo Cazzato, Antonella Daniele, Erica Silvestris, Gennaro Cormio, Giovanni Di Vagno, Antonio Malvasi, Vera Loizzi, Salvatore Scacco, Vincenzo Pinto, Ettore Cicinelli, Eugenio Maiorano, Giuseppe Ingravallo, Leonardo Resta, Carla Minoia, and Miriam Dellino
- Subjects
General Immunology and Microbiology ,General Agricultural and Biological Sciences ,General Biochemistry, Genetics and Molecular Biology - Abstract
The heterogeneity of the cervico-vaginal microbiota can be appreciated in various conditions, both pathological and non-pathological, and can vary according to biological and environmental factors. Attempts are still in course to define the interaction and role of the various factors that constitute this community of commensals in immune protection, inflammatory processes, and the onset of precancerous lesions of the cervical epithelium. Despite the many studies on the relationship between microbiota, immunity, and HPV-related cervical tumors, further aspects still need to be probed. In this review article, we will examine the principal characteristics of microorganisms commonly found in cervico-vaginal specimens (i) the factors that notoriously condition the diversity and composition of microbiota, (ii) the role that some families of organisms may play in the onset of HPV-dysplastic lesions and in neoplastic progression, and (iii) possible diagnostic-therapeutic approaches.
- Published
- 2022
24. HL-416: Late Toxicities and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Series of Systematic Reviews of the Fondazione Italiana Linfomi
- Author
-
Carla Minoia, Chiara Gerardi, Eleonora Allocati, Vitaliana De Sanctis, Silvia Franceschetti, Simonetta Viviani, Maria Antonietta Annunziata, Alessia Bari, Tetiana Skrypeta, Stefano Oliva, Agata Puzzovivo, Sergio Di Molfetta, Valentina Caccavari, Anna Di Russo, Giacomo Loseto, Antonella Daniele, Luca Nassi, Guido Gini, and Attilio Guarini
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2021
25. ARGO, Automatic Record Generator for Oncology: a natural language process-based tool to capture pathology features from onco-hematological reports (Preprint)
- Author
-
Gian Maria Zaccaria, Vito Colella, Simona Colucci, Felice Clemente, Fabio Pavone, Maria Carmela Vegliante, Flavia Esposito, Giuseppina Opinto, Antonio Negri, Giacomo Loseto, Carla Minoia, Bernardo Rossini, Vito Angiulli, Angela Maria Quinto, Laura Schirosi, Anna Scattone, Alfredo Zito, Luigi Alfredo Grieco, Attilio Guarini, and Sabino Ciavarella
- Abstract
BACKGROUND The unstructured nature of medical data from Real-World (RW) patients and the scarce accessibility for researchers to integrated systems restrain the use of RW information for clinical and translational research purposes. Natural Language Processing (NLP) might help in transposing unstructured reports in electronic health records (EHR), thus prompting their standardization and sharing. OBJECTIVE We aimed at designing a tool to capture pathological features directly from hemo-lymphopathology reports and automatically record them into electronic case report forms (eCRFs). METHODS We exploited Optical Character Recognition and NLP techniques to develop a web application, named ARGO (Automatic Record Generator for Oncology), that recognizes unstructured information from diagnostic paper-based reports of diffuse large B-cell lymphomas (DLBCL), follicular lymphomas (FL), and mantle cell lymphomas (MCL). ARGO was programmed to match data with standard diagnostic criteria of the National Institute of Health, automatically assign diagnosis and, via Application Programming Interface, populate specific eCRFs on the REDCap platform, according to the College of American Pathologists templates. A selection of 239 reports (n. 106 DLBCL, n.79 FL, and n. 54 MCL) from the Pathology Unit at the IRCCS - Istituto Tumori “Giovanni Paolo II” of Bari (Italy) was used to assess ARGO performance in terms of accuracy, precision, recall and F1-score. RESULTS By applying our workflow, we successfully converted 233 paper-based reports into corresponding eCRFs incorporating structured information about diagnosis, tissue of origin and anatomical site of the sample, major molecular markers and cell-of-origin subtype. Overall, ARGO showed high performance (nearly 90% of accuracy, precision, recall and F1-score) in capturing identification report number, biopsy date, specimen type, diagnosis, and additional molecular features. CONCLUSIONS We developed and validated an easy-to-use tool that converts RW paper-based diagnostic reports of major lymphoma subtypes into structured eCRFs. ARGO is cheap, feasible, and easily transferable into the daily practice to generate REDCap-based EHR for clinical and translational research purposes.
- Published
- 2021
26. 18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis
- Author
-
Maria Carmela Vegliante, Attilio Guarini, K. Filonenko, Benedetta Puccini, Tetiana Skrypets, Gianmauro Sacchetti, Felice Clemente, Luca Nassi, Cristina Ferrari, Gloria Margiotta Casaluci, Lara Mannelli, Carla Minoia, Irina Kryachok, and Antonella Daniele
- Subjects
medicine.medical_specialty ,Concordance ,lcsh:Medicine ,Medicine (miscellaneous) ,Colonoscopy ,Asymptomatic ,Article ,03 medical and health sciences ,0302 clinical medicine ,medicine ,endoscopy ,gastric biopsy ,medicine.diagnostic_test ,business.industry ,Stomach ,Mantle Cell Lymphoma ,lcsh:R ,18F-FDG PET/CT ,Retrospective cohort study ,staging ,colorectal biopsy ,medicine.disease ,Endoscopy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Mantle cell lymphoma ,Radiology ,medicine.symptom ,business ,030215 immunology ,Cohort study - Abstract
The detection of gastrointestinal (GI) involvement in Mantle Cell Lymphoma is often underestimated and may have an impact on outcome and clinical management. We aimed to evaluate whether baseline 18F-FDG PET/CT presents comparable results to endoscopic biopsy in the diagnosis of GI localizations. In our retrospective cohort of 79 patients, sensitivity and specificity of 18F-FDG PET/CT were low for the stomach, with a fair concordance (k = 0.32), while higher concordance with pathologic results (k = 0.65) was detected in the colorectal tract. Thus, gastric biopsy remains helpful in the staging of MCL despite 18F-FDG PET/CT, while colonoscopy could be omitted in asymptomatic patients. The validation of our data in prospective cohorts is desirable
- Published
- 2021
27. A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?
- Author
-
Miriam Dellino, Gennaro Cormio, Carla Minoia, Vito Michele Garrisi, Porzia Casamassima, Giulio Gargano, Erica Silvestris, Skrypets Tetania, Antonio Tufaro, Vera Loizzi, Angelo Paradiso, Carmine Carriero, and Raffele Tinelli
- Subjects
medicine.medical_specialty ,Observational Study ,Disease ,Strengthening the reporting of observational studies in epidemiology ,Gastroenterology ,Vulva ,03 medical and health sciences ,0302 clinical medicine ,WAP Four-Disulfide Core Domain Protein 2 ,Internal medicine ,Paget Disease ,Medicine ,human epididymis protein 4 ,Humans ,030212 general & internal medicine ,Prospective Studies ,Aged ,Aged, 80 and over ,Receiver operating characteristic ,business.industry ,Significant difference ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Paget disease of the vulva ,cancer antigen125 ,medicine.anatomical_structure ,Paget Disease, Extramammary ,ROC Curve ,030220 oncology & carcinogenesis ,CA-125 Antigen ,Observational study ,Female ,Vulvar Diseases ,business ,Biomarkers ,Research Article - Abstract
Paget disease is a complex disorder that can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget's disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and recurrence can negatively impact the prognosis. Therefore, the main objective of this study is to evaluate if the human epididymis protein 4 (HE4) and cancer antigen125 (CA125) can promote recognition of PVD in early stages and during the relapses. we have conducted a prospective, observational and laboratory-based study, that included 50 patients, whose 25 healthy women represented the control group and 25 PVD patients, which have been operated in our Oncology Institute, from May 2017 to September 2019. Both in the control group and in PVD patients, the CA-125 and HE4 were evaluated before surgery and after 6 months. Finally, a comparison of markers serum level, both between before/after surgery and with control group, and a ROC (Receiver Operating Characteristic) curve were performed. Dosing the markers in PVD patients, 3/25 (12%) showed a higher value of CA125 and 11/25 (44%) an increased HE4. In addition, after surgical treatment there were no statistically significant difference between levels of CA-125 (P = .3) and HE4 (P = .19). On the other hand, comparing HE4 in PVD patients with the control group, a statistically significant difference was found (P-value = .0036). Contrary, comparing CA-125 in PVD patients with the control group (P-value= .1969), no statistically significant difference was evidenced. Moreover, ROC (Receiver Operating Characteristic) curve showed low sensitivity and specificity for CA125 with area under curve (AUC) = 0.5608. Instead, the ROC curve of HE4 revealed a sensitivity and specificity of 76% and 88% respectively (AUC = 0.7408) using a cut-off at 90 pmol/L. Despite the limited cases, our data showed that CA125 is not a sensitive marker for PVD. On the other hand, in 44% of PVD we’ve seen an increase in HE4. So, this could be a starting point for further research that could confirm the possibility to use this marker in order to support PVD early identification.
- Published
- 2020
28. Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?
- Author
-
Miriam Dellino, Giulio Gargano, Carmine Carriero, Carla Minoia, Tetania Skrypets, Erica Silvestris, Vera Loizzi, Angelo Paradiso, Porzia Casamassima, Antonio Tufaro, Gennaro Cormio, and Vito Michele Garrisi
- Abstract
Background: Paget disease is a rare neoplasia, most commonly diagnosed in postmenopausal women and which can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget’s disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and recurrence can negatively impact the prognosis. Therefore, the main objective of this study is to evaluate if the human epididymis protein 4 (HE4) and cancer antigen125 (CA125) can promote recognition of PVD in early stages and during the relapses.Materials and Methods: we have conducted a prospective, observational and laboratory-based study, that included 50 patients, whose 25 healthy women represented the control group and 25 PVD patients, which have been operated in our Oncology Institute, from May 2017 to September 2019. Both in control group and in PVD patients, the CA-125 and HE4 were evaluated before surgery and after 6 months. Finally, a comparison of markers serum level, both between before/after surgery and with control group, and a ROC (Receiver Operating Characteristic) curve were performed.Results: Dosing the markers in PVD patients, 3/25 (12%) showed a higher value of CA125 and 11/25 (44%) an increased HE4. In addition, after surgical treatment there were no statistically significant difference between levels of CA-125 (p= 0.3) and HE4 (p=0.19). On the other hand, comparing HE4 in PVD patients with the control group, a statistically significant difference was found (p-value= 0.0036). Contrary, comparing CA-125 in PVD patients with the control group (p-value= 0.1969), no statistically significant difference was evidenced. Moreover, ROC (Receiver Operating Characteristic) curve showed low sensitivity and specificity for CA125 with area under curve (AUC) =0.5608. Instead, the ROC curve of HE4 revealed a sensitivity and specificity of 76% and 88% respectively (AUC= 0.7408) using a cut-off at 90 pmol/L.Conclusions: Despite the limited cases, our data showed that CA125 is not a sensitive marker for PVD. On the other hand, in 44% of PVD we’ve seen an increase in HE4. So, this could be a starting point for further research that could confirm the possibility to use this marker in order to support PVD early identification.
- Published
- 2020
29. The Role of Circulating Adiponectin and SNP276GT at
- Author
-
Antonella, Daniele, Angelo Virgilio, Paradiso, Rosa, Divella, Maria, Digennaro, Margherita, Patruno, Stefania, Tommasi, Brunella, Pilato, Antonio, Tufaro, Michele, Barone, Carla, Minoia, Donatella, Colangelo, Eufemia, Savino, Porzia, Casamassima, Eleonora, Bruno, Andreina, Oliverio, and Patrizia, Pasanisi
- Subjects
BRCA2 Protein ,Ovarian Neoplasms ,Genotype ,BRCA1 Protein ,Breast Neoplasms ,Middle Aged ,Prognosis ,Polymorphism, Single Nucleotide ,Case-Control Studies ,Mutation ,Biomarkers, Tumor ,Humans ,Female ,Genetic Predisposition to Disease ,Adiponectin ,Retrospective Studies ,Research Article - Abstract
Background: Environmental factors may influence the lifetime risk of cancer (penetrance) in women with a BRCA mutation. Materials and Methods: In 89 BRCA-mutant women, affected or unaffected by breast/ovarian cancer, we explored serum levels of adipokines and their relation with the polymorphism SNP276G>T as modulators of BRCA penetrance. Results: Affected women had significantly lower adiponectin than healthy women. Affected women with rs1501299 TT had significantly lower adiponectin and higher leptin than GT and GG genotypes. GT genotype was significantly associated with the disease status [odds ratio (OR)=3.24, 95% confidence interval (95% CI)=1.03-10.17]. Women in the lower tertile of serum adiponectin had a RR of BRCA-associated cancer of 2.80, 95% CI=1.1-7.1 (p for trend=0.03) compared with women in the higher tertile. Conclusion: In the SNP rs1501299 the T allele was significantly associated with lower serum levels of adiponectin in affected women, suggesting that the T allele might be related to cancer.
- Published
- 2020
30. Can18F-FDG PET/CT overcome endoscopy in the staging of gastrointestinal involvement in Mantle Cell Lymphoma? A retrospective multi-center cohort analysis
- Author
-
Tetiana Skrypets, Luca Nassi, Gloria Margiotta Casaluci, Benedetta Puccini, Lara Mannelli, Sofya Kovalchuk, Kateryna Filonenko, Irina Kryachok, Angela Monica Sciacovelli, Maria Carmela Vegliante, Antonella Daniele, Gianmauro Sacchetti, Cristina Ferrari, Attilio Guarini, and Carla Minoia
- Abstract
Background. Mantle-cell lymphoma (MCL) represents the 5-7% of all lymphoid malignancies. In 15-30% of cases by different data, MCL may affect the gastrointestinal tract (GI), but the real frequency by endoscopy and imaging could be significantly higher. Actually, by guidelines there are no recommendations for GI endoscopy in every patient with MCL. Therefore, we conducted the present multi-center study with the aim to evaluate the performance of the 18F-FDG PET/CT in the detection of GI involvement in patients with MCL and establish whether it is possible to omit endoscopy.Methods. We retrospectively evaluated 79 patients with newly diagnosed MCL, who had performed a pretreatment 18F-FDG PET/CT scan and GI endoscopy with biopsy. Results. By PET/CT, overall GI tract involvement was found in 24% of patients. The performance of PET/CT have been evaluated by sensitivity, specificity, positive predictive value, negative predictive value and accuracy in the upper and lower GI tract. Using Cohen's k test, PET/CT and EGD with biopsy showed a fair agreement (0.20, 66.6%). However, PET/CT and colorectal biopsy showed a moderate agreement (0.49, 76%). Conclusion. Analyzed data suggest that the performance of 18F-FDG PET/CT is not excellent in the detection of gastric lesions by MCL, and thus EGD with biopsy has yet to be considered a "golden standard" in this subset, while colonoscopy could be omitted due to a higher accuracy and specificity. Taking into account the limit of the retrospective nature of the study, data should be confirmed on larger and prospective cohort.
- Published
- 2020
31. Novel aspects on gonadotoxicity and fertility preservation in lymphoproliferative neoplasms
- Author
-
Attilio Guarini, Tetiana Skrypets, Angelo Paradiso, Gennaro Cormio, Miriam Dellino, Erica Silvestris, and Carla Minoia
- Subjects
0301 basic medicine ,Infertility ,Male ,Ovarian Cortex ,media_common.quotation_subject ,Fertility ,Antineoplastic Agents ,Primary Ovarian Insufficiency ,Bioinformatics ,Regenerative medicine ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Female patient ,medicine ,Humans ,Fertility preservation ,media_common ,Cryopreservation ,business.industry ,Ovary ,Chemotherapy ,Lymphoma ,Lymphoproliferative neoplasms ,Ovarian function ,Targeted therapies ,Female ,Lymphoproliferative Disorders ,Oocytes ,Fertility Preservation ,Cancer ,Hematology ,Oocyte cryopreservation ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,business - Abstract
The topic of fertility preservation in patients with a lymphoproliferative disease offers new aspects of debate, due to the introduction of novel chemotherapeutic regimens and small molecules in the clinical landscape. Cancer related infertility is mostly dependent on gonadotoxic treatments and fertile female patients are today addressed to the oocyte cryopreservation or to ovarian cortex fragment cryopreservation. These methods present advantages and disadvantages, which will be discussed in the present review, together with the options for male patients. The recent discovery of functional ovarian stem cells (OCSs) in woman ovarian cortex, opens new avenues offering a innovative procedure for fertility preservation through as model of regenerative medicine. Here, we review the gonadotoxic potential of “classical” chemotherapeutic treatments as well as of “novel” targeted therapies actually employed for lymphoproliferative neoplasms in young patients and revisit both the today available and future chances to preserve and restore fertility after the cancer healing.
- Published
- 2020
32. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study
- Author
-
Nicola Cascavilla, Felicina Li Gioi, Giuseppina Ricciuti, Maurizio Musso, Alessandra Crescimanno, Ferdinando Porretto, Gaetano De Santis, Emilio Iannitto, Annalisa Chiarenza, Ugo Consoli, Attilio Guarini, Maria Cristina Pirosa, Antonino Greco, Giuseppe Tarantini, Marilena Salerno, Saverio Mantuano, Carla Minoia, Donato Mannina, Francesco Di Raimondo, Alessandra Romano, Potito Rosario Scalzulli, Enzo Pavone, Renato Scalone, Anastasia Laura Caruso, and Vincenza Bonanno
- Subjects
Bendamustine ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,lymphoma ,Drug resistance ,Neutropenia ,Gastroenterology ,bendamustine hydrochloride ,brentuximab vedotin ,drug resistance ,Hodgkin disease ,recurrence ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Refractory ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Bendamustine Hydrochloride ,Humans ,Brentuximab vedotin ,Aged ,Brentuximab Vedotin ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Hodgkin Disease ,Lymphoma ,Regimen ,Treatment Outcome ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Toxicity ,Female ,business ,030215 immunology ,medicine.drug - Abstract
Objective and methods In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patients treated with BvB in second relapse or beyond were reviewed. Results The median number of previous treatments was 2 (1-4). Bv was given at 1.8 mg/kg on day 1 and bendamustine at 90 mg/m2 on days 1 and 2 of a 21-day cycle. The median number of BvB cycles was 4 (2-7), and all patients were evaluable for efficacy. The CR and OR rates were 49% and 79%, respectively; 67% of responding patients and 2 in stable disease proceeded to a SCT procedure. After a median follow-up of 19 months (5-47), median PFS was 18 months (95%CI: 23-29), and the 2-year OS was 72%. Significantly longer PFS and OS were observed in patients attaining a major clinical response to treatment and in those who received consolidation with SCT. Fifteen (32%) patients experienced severe (G > 2) toxicity. The main toxicities were neutropenia (23%), gastrointestinal (10%), peripheral sensory neuropathy (11%), and infection (4%). Conclusion Our real-world results suggest that BvB is an effective third-line rescue and bridge-to-transplant regimen for RR-cHL patients.
- Published
- 2020
33. Novel acquisitions on biology and management of transformed follicular lymphoma
- Author
-
Carla Minoia, Emanuele Zucca, and Annarita Conconi
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,Cell ,Follicular lymphoma ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Tumor Microenvironment ,medicine ,Humans ,Epigenetics ,education ,Lymphoma, Follicular ,Prior treatment ,education.field_of_study ,Hematology ,General Medicine ,medicine.disease ,Cell Transformation, Neoplastic ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Rituximab ,Stem cell ,Watchful waiting ,030215 immunology ,medicine.drug - Abstract
Follicular lymphoma (FL) generally has an indolent clinical course, but in some patients, a histological transformation (HT) into aggressive entities may take place and often lead to a poorer survival. The rituximab era has seen an improved outcome of FL, including those with HT. The current treatment strategies for transformed FL are based on immunochemotherapy for the cases with HT at the time of diagnosis or as the first event after watchful waiting. Patients transforming after prior treatment of FL usually benefit from autologous stem cell transplant. Unfortunately, early assessment of the transformation risk remains elusive. Recent studies delved the mechanisms of HT, showing that this is a complex process, resulting from a number of epigenetic and genetic lesions occurring in the tumour cell population as well as progressive changes in the tumour microenvironment. This novel knowledge has prompted clinical investigations on a variety of new therapeutic strategies.
- Published
- 2018
34. Poster: HL-416: Late Toxicities and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Series of Systematic Reviews of the Fondazione Italiana Linfomi
- Author
-
Chiara Gerardi, Carla Minoia, Agata Puzzovivo, Vitaliana De Sanctis, Giacomo Loseto, Valentina Caccavari, Alessia Bari, Maria Antonietta Annunziata, Guido Gini, Eleonora Allocati, Tetiana Skrypeta, Stefano Oliva, Anna Di Russo, Luca Nassi, Simonetta Viviani, Silvia Franceschetti, Antonella Daniele, Attilio Guarini, and Sergio Di Molfetta
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Series (stratigraphy) ,business.industry ,Hematology ,medicine.disease ,Systematic review ,Internal medicine ,Long term monitoring ,Classical Hodgkin lymphoma ,Medicine ,business ,Diffuse large B-cell lymphoma - Published
- 2021
35. Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
- Author
-
Attilio Guarini, Maria Antonietta Annunziata, Eleonora Allocati, Chiara Gerardi, Silvia Franceschetti, Carla Minoia, and Giulia Agostinelli
- Subjects
Cancer Research ,Pediatrics ,medicine.medical_specialty ,diffuse large B-cell lymphoma ,MEDLINE ,Cochrane Library ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Medicine ,RC254-282 ,cognitive impairment ,business.industry ,Incidence (epidemiology) ,Neuropsychology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,survivors ,anxiety ,medicine.disease ,classical Hodgkin lymphoma ,Systematic review ,quality of life ,Oncology ,030220 oncology & carcinogenesis ,depression ,Anxiety ,neuropathy ,fatigue ,Systematic Review ,medicine.symptom ,business ,Diffuse large B-cell lymphoma ,030215 immunology - Abstract
Simple Summary The last 25 years have seen a significant increase in the number of lymphoma survivors. This review was carried out to examine the data currently available on the incidence of some of the consequences most reported by this population: peripheral neuropathy, cognitive impairment, fatigue, and anxiety and depression. This review also investigated any follow-up strategies or monitoring implemented. The 35 articles included in the final analysis provided an idea of what the incidence of these sequelae may be in long-term survivors of classical Hodgkin lymphoma and diffuse large B-cell lymphoma. Despite methodological limitations encountered in the literature search, the Authors attempted to summarize the available evidence and provide support to clinical practice. This systematic review represents the basis for designing future studies with a longitudinal trial design and examining more homogeneous populations to assess and monitor these dimensions over time in clinical practice and to respond promptly to the needs of lymphoma survivors. Abstract Background: The continuously improving treatment outcome for classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) over the last 25 years has led to a high number of long-term survivors. The impact of treatment, however, can sometimes be dramatic and long-lasting. Focusing on peripheral neuropathy (PN), cognitive impairment, fatigue, anxiety, and depression, researchers of the Fondazione Italiana Linfomi conducted a systematic review of the literature to collect the available data on sequelae incidence as well as evidence of follow-up strategies for long-term cHL and DLBCL survivors. Methods: The review was carried out under the methodological supervision of the Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy. The literature search was conducted on three databases (MEDLINE, Embase, and the Cochrane Library) updated to November 2019. The selection process and data extraction were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A total of 2236 abstracts were screened, 247 full texts were analyzed, and 35 papers were included in the final analysis. Fatigue was the most extensively studied among neuropsychological sequelae, with a mean prevalence among cHL survivors of 10–43%. Although many of the papers showed an increased incidence of PN, cognitive impairment, and anxiety and depression in long-term cHL and DLBCL survivors, no definite conclusions can be drawn because of the methodological limitations of the analyzed studies. No data on monitoring and follow-up strategies of PN and other neuropsychological sequelae were highlighted. Conclusions: Based on our findings, future studies in this setting should include well-defined study populations and have a longitudinal trial design to assess the outcomes of interest over time, thus as to structure follow-up programs that can be translated into daily practice.
- Published
- 2021
36. Is whole body low dose CT still necessary in the era of
- Author
-
Nicola, Maggialetti, Cristina, Ferrari, Anna Giulia, Nappi, Angela, Quinto, Bernardo, Rossini, Marcello, Zappia, Carla, Minoia, Attilio, Guarini, Luca, Brunese, and Giuseppe, Rubini
- Subjects
Adult ,Male ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Humans ,Female ,Whole Body Imaging ,Bone Diseases ,Middle Aged ,Multiple Myeloma ,Radiation Dosage - Abstract
Whole body low dose computed tomography (WBLDCT) is the first-choice imaging modality to identify bone involvement in multiple myeloma (MM). Because the unenhanced LDCT co-registered to positron emission tomography (PET) (LDCT/PET) has similar technical characteristics to WBLDCT, we aimed to assess its reliability in the detection of bone disease, for employing fluorine-18-fluorodeoxyglucose (Thirty three consecutive MM patients were prospectively enrolled and evaluated with WBLDCT to assess bone involvement. In addition, patients underwentThe two imaging modalities resulted highly concordant considering both patient-based (k=0.841) and region-based analysis; some discrepancies were observed in dorsal spine (k=0.809) and thorax (k=0.756). Low dose computed tomography/PET sensitivity, specificity and accuracy were 89.4%, 98.3% and 93.5%, respectively.Low dose computed tomography co-registered PET has comparable performance to WBLDCT. If confirmed on a lager sample, these encouraging results suggest the possibility to use this multimodal hybrid imaging as the only method for MM evaluation, rather than both exams, providing both morphologic and metabolic information in one session with impact on patient compliance, health care spending and especially radiation exposure.
- Published
- 2019
37. 1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia
- Author
-
Clelia Tiziana Storlazzi, Giulia Daniele, Antonella Turchiano, Crocifissa Lo Cunsolo, María Hernández-Sánchez, Patrizia Leone, P. Iuzzolino, Angelo Lonoce, Carla Minoia, Orazio Palumbo, Massimo Carella, Jesús María Hernández-Rivas, Alberto L'Abbate, and Associazione Italiana per la Ricerca sul Cancro
- Subjects
Male ,0301 basic medicine ,1q23.1 deletion ,IGHV ,Derivative chromosome ,Chronic lymphocytic leukemia ,Down-Regulation ,Translocation ,Chromosomal translocation ,Receptors, Fc ,Biology ,medicine.disease_cause ,Translocation, Genetic ,General Biochemistry, Genetics and Molecular Biology ,Frameshift mutation ,03 medical and health sciences ,0302 clinical medicine ,NOTCH1 ,medicine ,Humans ,Pathology, Molecular ,Gene ,Aged ,Sequence Deletion ,Mutation ,Chromosomes, Human, 1-3 ,General Medicine ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,030104 developmental biology ,FCRL ,030220 oncology & carcinogenesis ,Cancer research ,IGHV@ ,CLL ,SNP array - Abstract
The identification of chromosome 1 translocations and deletions is a rare and poorly investigated event in chronic lymphocytic leukemia (CLL). Nevertheless, the identification of novel additional molecular alterations is of great interest, opening to new prognostic and therapeutic strategies for such heterogeneous hematological disease. We here describe a patient affected by CLL with a mutated IGHV status, showing a balanced t(1;3)(q23.1;q21.3) translocation and a der(18)t(1;18)(q24.2;p11.32), accompanying the recurrent 13q14 heterozygous deletion in all analyzed cells at onset. By combining whole-genome sequencing, SNP array, RNA sequencing, and FISH analyses, we defined a 1q23.1 biallelic minimally deleted region flanking translocations breakpoints at both derivative chromosome 1 homologues. The deletion resulted in the downregulation of the Fc receptor-like family genes FCRL1, FCRL2, and FCRL3 and in the lack of expression of FCRL5, observed by RT-qPCR. The mutational status of TP53, NOTCH1, SF3B1, MYD88, FBXW7, and XPO1 was investigated by targeted next-generation sequencing, detecting a frameshift deletion within NOTCH1 (c.7544_7545delCT). We hypothesize a loss of tumor suppressor function for FCRL genes, cooperating with NOTCH1 mutation and 13q14 genomic loss in our patient, both conferring a negative prognosis, independently from the known biological prognostic factors of CLL., This work was supported by the AIRC (Associazione Italiana per la Ricerca sul Cancro; AIRC IG No. 15413 for CTS).
- Published
- 2019
38. Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkin’s Lymphoma Survivors
- Author
-
E. Savino, Paolo Ditonno, S. De Summa, Porzia Casamassima, Antonella Daniele, Angelo Paradiso, Carla Minoia, R. Divella, G. Lerario, Attilio Guarini, S. Ciavarella, M. D. Carbonara, and Miriam Dellino
- Subjects
medicine.medical_specialty ,diffuse large B-cell lymphoma ,lcsh:Medicine ,Medicine (miscellaneous) ,unhealthy lifestyle ,Article ,metabolic syndrome ,sarcopenia ,03 medical and health sciences ,0302 clinical medicine ,Insulin resistance ,Internal medicine ,Medicine ,Abdominal obesity ,030304 developmental biology ,0303 health sciences ,Univariate analysis ,non-Hodgkin’s lymphoma survivors ,business.industry ,lcsh:R ,Metabolic disorder ,steroid use ,medicine.disease ,Non-Hodgkin's lymphoma ,030220 oncology & carcinogenesis ,Sarcopenia ,body composition change ,medicine.symptom ,Metabolic syndrome ,business ,Weight gain - Abstract
Unhealthy lifestyle, as sedentary, unbalanced diet, smoking, and body composition change are often observed in non-Hodgkin’s lymphoma (NHL) survivors, and could be determinant for the onset of cancer treatment-induced metabolic syndrome (CTIMetS), including abdominal obesity, sarcopenia, and insulin resistance. The aim of this study was to assess whether changes in body composition, unhealthy lifestyles and types of anti-cancer treatment could increase the risk of metabolic syndrome (MetSyn) and sarcopenia in long-term NHL survivors. We enrolled 60 consecutive NHL patients in continuous remission for at least 3 years. Nutritional status was assessed by anthropometry-plicometry, and a questionnaire concerning lifestyles and eating habits was administered. More than 60% of survivors exhibited weight gain and a change in body composition, with an increased risk of MetSyn. Univariate analysis showed a significantly higher risk of metabolic disorder in patients treated with steroids, and in patients with unhealthy lifestyles. These data suggest that a nutritional intervention, associated with adequate physical activity and a healthier lifestyle, should be indicated early during the follow-up of lymphoma patients, in order to decrease the risk of MetSyn’s onset and correlated diseases in the long term.
- Published
- 2021
39. Germinal ovarian tumors in reproductive age women
- Author
-
Carla Minoia, Vera Loizzi, Angelo Paradiso, Miriam Dellino, Erica Silvestris, Rosalia Maria Rita Loiacono, Gennaro Cormio, and Antonella Daniele
- Subjects
medicine.medical_specialty ,Hysterectomy ,business.industry ,Obstetrics ,medicine.medical_treatment ,media_common.quotation_subject ,Fertility ,General Medicine ,medicine.disease ,03 medical and health sciences ,Omentectomy ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Lymphadenectomy ,Stage IIIC ,030212 general & internal medicine ,Germ cell tumors ,Young adult ,Radical surgery ,business ,media_common - Abstract
MOGCTs (malignant ovarian germ cell tumors) are rare tumors that mainly affect patients of reproductive age. The aim of this study was to evaluate the fertility and survival outcomes in young women with MOCGTs treated with fertility-sparing surgery (FSS).From 2000 to 2018, data from 28 patients of reproductive age with a diagnosis of MOGCT at the University of Bari were collected. Most received FSS, and in patients treated conservatively, the reproductive outcome and survival were investigated. Data of patient demographics, clinical presentation, oncology marker dosage, staging, type of surgery, histological examination, survival, and reproductive outcome were collected from hospital and office charts. All informed consent was obtained from all patients. The median age was 24 (range: 9-45 years). The majority of the patients had stage IIIC. Twenty-four woman received FSS consisting of unilateral ovariectomy and omentectomy, whereas only 4 women, based on their stage (IIIC), received a radical surgery (hysterectomy with bilateral adnexectomy, lymphadenectomy, and omentectomy). Our study shows that FSS in MOGCTs can produce good results both on reproductive outcomes and on survival. Indeed, in our group, there was only 1 case of exitus as result of recurrence. Furthermore, patients after FSS maintained normal ovarian function and 5 of 5 women who tried to get pregnant succeeded spontaneously. The median follow-up was 90 months (range 3-159).Conservative surgery for MOGCTs should be considered for women of reproductive age who wish to preserve fertility.
- Published
- 2020
40. Improvable Lifestyle Factors in Lymphoma Survivors
- Author
-
Attilio Guarini, Carla Minoia, Simona De Summa, Giovanna Lerario, Antonella Daniele, Sabino Ciavarella, and Mariarosaria Napolitano
- Subjects
Gerontology ,Adult ,Male ,Lymphoma ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Quality of life (healthcare) ,Public health surveillance ,Cancer Survivors ,Medicine ,Humans ,Public Health Surveillance ,030212 general & internal medicine ,Young adult ,Life Style ,Aged ,Aged, 80 and over ,business.industry ,Life style ,Lymphoma diagnosis ,Follow up studies ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Lifestyle factors ,Italy ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,business ,Follow-Up Studies - Published
- 2018
41. Improving Provision of Care for Long-term Survivors of Lymphoma
- Author
-
Santa Carbonara, Angela Maria Quinto, Carla Minoia, Stefano Oliva, Michele Spina, Giacomo Loseto, Mariarosaria Napolitano, Filippo Santoro, Elena Bravo, Maria Christina Cox, Claudia Cormio, Sabino Ciavarella, and Attilio Guarini
- Subjects
Cancer Research ,medicine.medical_specialty ,Lymphoma ,Health Promotion ,030204 cardiovascular system & hematology ,Affect (psychology) ,Care provision ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Risk Factors ,Survivorship curve ,medicine ,Humans ,Survivors ,Intensive care medicine ,Adverse effect ,Fatigue ,Cardiopulmonary disease ,business.industry ,Neoplasms, Second Primary ,Hematology ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,Life expectancy ,Physical therapy ,Quality of Life ,business ,Delivery of Health Care - Abstract
The progressive improvement of lymphoma therapies has led to a significant prolongation of patient survival and life expectancy. However, lymphoma survivors are at high risk of experiencing a range of early and late adverse effects associated with the extent of treatment exposure. Among these, second malignancies and cardiopulmonary diseases can be fatal, and neurocognitive dysfunction, endocrinopathy, muscle atrophy, and persistent fatigue can affect patients' quality of life for decades after treatment. Early recognition and reduction of risk factors and proper monitoring and treatment of these complications require well-defined follow-up criteria, close coordination among specialists of different disciplines, and a tailored model of survivorship care. We have summarized the major aspects of therapy-related effects in lymphoma patients, reviewed the current recommendations for follow-up protocols, and described a new hospital-based model of survivorship care provision from a recent multicenter Italian experience.
- Published
- 2017
42. PF510 A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA
- Author
-
Claudio Agostinelli, Attilio Guarini, Alfredo Zito, Alessandro Gulino, Umberto Vitolo, M.C. Vegliante, Anna Scattone, S. Ciavarella, Giovanna Motta, Marco Fabbri, Giacomo Loseto, S. A. Pileri, Carla Minoia, Giuseppina Opinto, Claudio Tripodo, S. De Summa, Alessandro Rambaldi, A. Moschetta, S. Tommasi, Annalisa Chiappella, and Federica Melle
- Subjects
Tumor Infiltrating Macrophages ,Cancer research ,medicine ,Patient survival ,Hematology ,Cholesterol metabolism ,Gene signature ,Biology ,medicine.disease ,Diffuse large B-cell lymphoma - Published
- 2019
43. Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas
- Author
-
Giacoma De Tullio, A. Rana, Alessia L. Marzano, Eugenio Maiorano, Simona Serratì, Pasquale Iacopino, Angela Iacobazzi, Francesca Merchionne, Ida Galise, Carla Minoia, Francesco Alfredo Zito, Mariaconsilia Asselti, Attilio Guarini, Carmela Quero, Giovanni Simone, Giovanni Quintana, and Michela Casiello
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Angiogenesis ,Biopsy ,Pathogenesis ,Refractory ,Recurrence ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Lymphoma, Follicular ,Lymph node ,Aged ,Neovascularization, Pathologic ,medicine.diagnostic_test ,business.industry ,Lymphoma, Non-Hodgkin ,Hematology ,Middle Aged ,Hypoxia-Inducible Factor 1, alpha Subunit ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,HIF1A ,Hypoxia-inducible factors ,Disease Progression ,Cancer research ,Immunohistochemistry ,Female ,Lymph Nodes ,business - Abstract
Angiogenesis is involved in the pathogenesis and progression of non-Hodgkin lymphomas (NHL), and hypoxia-inducible factor-1α (HIF-1α, also termed HIF1A) might contribute to this process. Currently, there is no direct evidence that the clinical progression of indolent NHL is associated with angiogenesis, and the expression of HIF-1α at recurrence is unknown. Matched lymph node biopsies at diagnosis and recurrence of relapsed/refractory indolent NHL patients were analysed by immunohistochemical and morphometric analysis. We observed an increased vascular network and HIF-1α protein expression in the second biopsy, providing direct evidence that angiogenesis is an essential process for disease progression.
- Published
- 2013
44. Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography
- Author
-
A. Di Rocco, R. Guariglia, S. Falorio, P. C. Riccomagno, G. Doa, Benedetta Puccini, Erica Finolezzi, Rosanna Ciancia, A. Mulè, C. Filì, C. Toldo, S. Zanon, Stefano Volpetti, Carla Minoia, Francesco Zaja, A. Furlan, Marianna Sassone, Luca Nassi, Puccini, B., Nassi, L., Minoia, C., Volpetti, S., Ciancia, R., Riccomagno, P. C., Di Rocco, A., Mulè, A., Toldo, C., Sassone, M. C., Guariglia, R., Filì, C., Finolezzi, E., Falorio, S., Zanon, S., Furlan, A., Doa, G., and Zaja, F.
- Subjects
Male ,Staging ,Biopsy ,Bone marrow biopsy ,Computed tomography ,Hodgkinâs lymphoma ,Positron emission tomography ,Adolescent ,Adult ,Aged ,80 and over ,Bone Marrow ,Bone Marrow Examination ,Female ,Hodgkin Disease ,Humans ,Middle Aged ,Neoplasm Staging ,Positron Emission Tomography Computed Tomography ,Reproducibility of Results ,Retrospective Studies ,Sensitivity and Specificity ,Young Adult ,Hematology ,0302 clinical medicine ,Retrospective Studie ,Positive predicative value ,Stage (cooking) ,Radiation treatment planning ,Hodgkinâ s lymphoma ,Aged, 80 and over ,medicine.diagnostic_test ,General Medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Radiology ,Human ,medicine.medical_specialty ,Reproducibility of Result ,03 medical and health sciences ,medicine ,business.industry ,medicine.disease ,Hodgkin's lymphoma ,Lymphoma ,Bone marrow ,Nuclear medicine ,business ,Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography ,030215 immunology - Abstract
Several studies suggested that staging bone marrow biopsy (BMB) could be omitted in patients with classical Hodgkin's lymphoma (cHL) when a positron emission tomography/computed tomography (PET/CT) is performed at baseline.To address the concordance between BMB and PET/CT in the detection of bone marrow involvement (BMI) and the BMB role in determining the Ann Arbor stage, we retrospectively collected data on 1244 consecutive patients with cHL diagnosed from January 2007 to December 2013. One thousand eighty-five patients who had undergone both BMB and PET/CT were analyzed, comparing the Ann Arbor stage assessed with PET/CT only to that resulting from PET/CT combined with BMB.One hundred sixty-nine patients (16%) showed at least one focal skeletal lesion (FSL) at PET/CT evaluation. Only 55 patients had a positive BMB (5.1%); 34 of them presented at least one FSL at PET/CT. To the contrary, 895 out of 1030 patients with a negative BMB did not show any FSL (86.9%). Positive and negative predictive values of PET/CT for BMI were 20 and 98%, respectively; sensitivity and specificity were 62 and 87%, respectively. Fifty-four out of 55 patients with a positive BMB could have been evaluated as an advanced stage just after PET/CT; only one patient (0.1%) would have been differently treated without BMB.Our data showed a very high negative predictive value of PET/CT for BMI and a negligible influence of BMB on treatment planning, strengthening the recent indications that BMB could be safely omitted in cHL patients staged with PET/CT.
- Published
- 2016
45. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study
- Author
-
Raffaella Marcheselli, Attilio Guarini, Antonio Palumbo, Alessia Bari, Iolanda Vincelli, Federica Cocito, Carla Minoia, Elena Rivolti, Carla Mazzone, Alessandro Corso, Pellegrino Musto, Roberto Ria, Luigi Marcheselli, Fortunato Morabito, Giuseppe Mele, Massimo Gentile, Stefano Sacchi, Stefania Badiali, and Samantha Pozzi
- Subjects
Male ,Cancer Research ,Phases of clinical research ,Gastroenterology ,Dexamethasone ,0302 clinical medicine ,Multiple myeloma ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,Bendamustine Hydrochloride ,Lenalidomide ,Aged, 80 and over ,clinical trial ,Hematology ,Middle Aged ,Thalidomide ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Retreatment ,Disease Progression ,Female ,Multiple Myeloma ,medicine.drug ,Bendamustine ,Adult ,medicine.medical_specialty ,Maximum Tolerated Dose ,lenalidomide ,03 medical and health sciences ,Refractory ,Median follow-up ,Internal medicine ,medicine ,Humans ,bendamustine ,Survival analysis ,Aged ,Neoplasm Staging ,business.industry ,medicine.disease ,Survival Analysis ,Surgery ,Drug Resistance, Neoplasm ,business ,Biomarkers ,030215 immunology - Abstract
Lenalidomide and dexamethasone are an effective treatment for naive and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose “level 0”: bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1–21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.
- Published
- 2016
46. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression
- Author
-
Attilio Guarini, Angela Iacobazzi, Francesca Merchionne, Carla Minoia, Anastasia Chillà, Rosanna Lacalamita, Stefania Tommasi, A. Rana, Anna Laurenzana, S. De Summa, Gabriella Fibbi, Francesca Margheri, Simona Serratì, Brunella Pilato, Sabino Ciavarella, and M. Del Rosso
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Stromal cell ,Cancer-associated fibroblasts (CAF) Fibroblast activation Multiple myeloma microenvironment U-PAR ,Flow cytometry ,Receptors, Urokinase Plasminogen Activator ,Fibroblast activation ,Extracellular matrix ,03 medical and health sciences ,0302 clinical medicine ,Stroma ,Cancer-Associated Fibroblasts ,Cell Movement ,Genetics ,Tumor Cells, Cultured ,Medicine ,Humans ,Multiple myeloma ,Aged ,Cell Proliferation ,Neoplasm Staging ,medicine.diagnostic_test ,business.industry ,Multiple myeloma microenvironment ,Membrane Proteins ,medicine.disease ,Urokinase-Type Plasminogen Activator ,Matrix Metalloproteinases ,Up-Regulation ,Cancer-associated fibroblasts (CAF) ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Cell culture ,u-PAR ,030220 oncology & carcinogenesis ,Cancer research ,Disease Progression ,Female ,Bone marrow ,business ,Multiple Myeloma ,Monoclonal gammopathy of undetermined significance ,Research Article - Abstract
Background Multiple Myeloma (MM) is a B-cell malignancy in which clonal plasma cells progressively expand within the bone marrow (BM) as effect of complex interactions with extracellular matrix and a number of microenvironmental cells. Among these, cancer-associated fibroblasts (CAF) mediate crucial reciprocal signals with MM cells and are associated to aggressive disease and poor prognosis. A large body of evidence emphasizes the role of the urokinase plasminogen activator (u-PA) and its receptor u-PAR in potentiating the invasion capacity of tumor plasma cells, but little is known about their role in the biology of MM CAF. In this study, we investigated the u-PA/u-PAR axis in MM-associated fibroblasts and explore additional mechanisms of tumor/stroma interplay in MM progression. Methods CAF were purified from total BM stromal fraction of 64 patients including monoclonal gammopathy of undetermined significance, asymptomatic and symptomatic MM, as well as MM in post-treatment remission. Flow cytometry, Real Time PCR and immunofluorescence were performed to investigate the u-PA/u-PAR system in relation to the level of activation of CAF at different stages of the disease. Moreover, proliferation and invasion assays coupled with silencing experiments were used to prove, at functional level, the function of u-PAR in CAF. Results We found higher activation level, along with increased expression of pro-invasive molecules, including u-PA, u-PAR and metalloproteinases, in CAF from patients with symptomatic MM compared to the others stages of the disease. Consistently, CAF from active MM as well as U266 cell line under the influence of medium conditioned by active MM CAF, display higher proliferative rate and invasion potential, which were significantly restrained by u-PAR gene expression inhibition. Conclusions Our data suggest that the stimulation of u-PA/u-PAR system contributes to the activated phenotype and function of CAF during MM progression, providing a biological rationale for future targeted therapies against MM.
- Published
- 2016
47. Improvements in haematology for home health assistance and monitoring by a web based communication system
- Author
-
Carla Minoia, Angelo Galiano, Giovanni Nardelli, Roberto Bonaduce, Alessandro Massaro, Bachir Boussahel, Francesco Tarulli, Leonardo Pellicani, Vincenza De Fazio, Attilio Guarini, Antonio Negri, Caterina Marchionna, Lino Renna, Donato Barbuzzi, Giacoma De Tullio, and Sabino Ciavarella
- Subjects
Web server ,Engineering ,business.industry ,Big data ,020207 software engineering ,Cloud computing ,02 engineering and technology ,Certification ,021001 nanoscience & nanotechnology ,computer.software_genre ,Communications system ,World Wide Web ,Engineering management ,Server ,0202 electrical engineering, electronic engineering, information engineering ,Web application ,0210 nano-technology ,business ,computer ,Software measurement - Abstract
The authors have developed, in the field of a national project, an innovative communication system based on a web cloud platform oriented on the home-monitoring and home-assistance useful for de-hospitalization process. The goal of the work is to provide a tool for the hospital, able to manage different certified medical devices measuring data from patients at home. This management is provided by a web server system compatible with different devices and by a front-end panel able to register and to store data coming from these devices. The innovation is manly in the possibility to transfer the analyses from home to hospital thus reducing costs and providing more assistance and support to patients. The implemented database system represents a first step for future scientific studies and predictions requiring BigData storage.
- Published
- 2016
48. mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma
- Author
-
Nicola Silvestris, A. Rana, Angela Lapietra, C. D. Gadaleta, Angela Iacobazzi, Attilio Guarini, Girolamo Ranieri, Carla Minoia, M. Giannoccaro, and A. Raimondi
- Subjects
Cell cycle checkpoint ,Stromal cell ,Angiogenesis ,Down-Regulation ,mTORC1 ,Pharmacology ,Biology ,Biochemistry ,Recurrence ,Drug Discovery ,medicine ,Refractory Hodgkin Lymphoma ,Humans ,Everolimus ,PI3K/AKT/mTOR pathway ,Sirolimus ,Clinical Trials as Topic ,Cell growth ,TOR Serine-Threonine Kinases ,Organic Chemistry ,Hodgkin Disease ,Cancer research ,Molecular Medicine ,Signal Transduction ,medicine.drug - Abstract
Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) are available and there is a need for new compounds development. A number of promising agents with multiple mechanisms of action are under investigation. Microenvironment and neoangiogenesis are acquiring a rising relevance in the pathophysiology and progression of HL. Everolimus (RAD001) is an oral antineoplastic agent derived from rapamycin, a macrocyclic lactone antibiotic, targeting the mammalian target of rapamycin (mTOR). Although the importance of mTOR signaling in the deregulated cell growth of human neoplastic cells has been recognized, this pathway is also emerging as a key regulator of the tumor response to hypoxia, as well as endothelial and stromal cells function, thereby regulating neoangiogenesis. Furthermore, mTOR plays an important role in anticancer drug resistance. The actions of everolimus within the mTOR pathway in HL result in decreased protein synthesis and cell cycle arrest, as well as in decreased angiogenesis. Everolimus has shown preliminary evidence of efficacy as a single-agent in heavily pretreated relapsed/refractory HL, with an overall fair safety profile. The purpose of this review is to discuss the employment of everolimus as an antiproliferative and antiangiogenic agent in HL and to report the critical role of the mTOR pathway and angiogenesis in this malignancy.
- Published
- 2012
49. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA 'TRANSFORMED' BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE
- Author
-
Vittoria Tarantino, Guillaume Cartron, Clémentine Sarkozy, Miguel Alcoceba, Carla Minoia, Sara Alonso, Luana Conte, Massimo Federico, C. Rusconi, Marielle J. Wondergem, F. Morschhauser, Eva Kimby, A. Lopez Guillermo, Martine E.D. Chamuleau, Gilles Salles, Emanuele Zucca, Silvia Montoto, Bertrand Coiffier, Luigi Marcheselli, Dolores Caballero, Igor Aurer, E. Paszkiewicz-Kozik, Sandra Lockmer, Djamila E. Issa, and M. G. Da Silva
- Subjects
Cancer Research ,business.industry ,Follicular lymphoma ,Hematology ,General Medicine ,medicine.disease ,Lymphoma ,03 medical and health sciences ,Transformation (genetics) ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,medicine ,Cancer research ,Rituximab ,business ,030215 immunology ,medicine.drug - Published
- 2017
50. A supervised CAD to support telemedicine in hematology
- Author
-
Anna Scattone, Ferdinando Giglio, Carla Minoia, Nicola Sgherza, Domenico Buongiorno, Loreto Gesualdo, Giacoma De Tullio, Attilio Guarini, Francesco Girardi, Giovanni Simone, Giacomo Tattoli, Pierluigi Carlucci, Alfredo Zito, and Vitoantonio Bevilacqua
- Subjects
Computer science ,business.industry ,Complexity theory ,Decision tree ,Image coding ,CAD ,Image processing ,Pattern recognition ,Machine learning ,computer.software_genre ,Ranking (information retrieval) ,Set (abstract data type) ,Blood ,Image resolution ,Ranking ,Plasmas ,Artificial Intelligence ,Test set ,Training ,Segmentation ,Artificial intelligence ,Software ,business ,computer - Abstract
This paper presents the design and the implementation of a Computer Aided Diagnosis (CAD) system for the clinical analysis of Peripheral Blood Smears (PBS also called Blood Film). The proposed system is able to count and classify the five types of leucocytes located in the tail of a PBS for computing the leukocyte formula. Image processing and segmentation techniques were used to extract 33 leucocyte's features (morphological, chromatic and texture-based). Only 7 features, selected by using the Information Gain Ranking algorithm of Weka platform, were used to evaluate the classification performance of two different classifiers: Back Propagation Neural Network (BPNN) and Decision Tree (DT). From the comparison between the two proposed approaches we can argue that the BPNN performed better than the DT on the validation set. Finally, the Neural Network classifier was evaluated with a test set composed of 1274 leucocytes obtaining good results in terms of Precision (87.9%) and Sensitivity (97.4%).
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.